MIC13 of Toxoplasma gondii: Potential Gene for Vaccine Candidate-An In Silico Approach

Purpose: Toxoplasmosis, which is the result of infection by Toxoplasma gondii (T. gondii), is a widespread parasitic disease that affects approximately one-third of the global population. Routine medications are not able to eradicate the parasites enclosed in cysts that reside inside the hosts that are infected. MIC13 is believed to have a significant function in facilitating the dissemination of the parasite throughout the host organism. The objective of this research was to utilize immunoinformatics techniques for antigenic analysis and structural prediction of the MIC13 protein, with the goal of identifying potential epitopes that could be used to create a vaccine for T. gondii. Materials and Methods: The current research was aimed at describing the chemical and physical features, subcellular localization, potential epitopes for B- and T-cells, transmembrane domain, tertiary and secondary structures, and other attributes of the MIC13 protein. Results: The results indicated that the MIC13 protein possesses a single N-glycosylation, 15 O-glycosylation regions, 70 phosphorylation sites, and five acetylation sites, with no transmembrane domains being detected within its structure. In terms of secondary structure, the MIC13 protein is composed of 27.99% alpha-helix, 16.45% extended strand, and 55.56% random coil elements. Additionally, various potential B- and T-cell epitopes were pinpointed for the MIC13 protein, suggesting its immunogenic properties. The assessment of antigenicity and allergenicity further confirmed that MIC13 is immunogenic but nonallergenic, making it a promising candidate for further study. Furthermore, the induction of IFN-γ and IL-4 highlighted the ability of related MHC-II molecules to interact with MIC13, indicating its potential role in immune responses. These findings shed light on the multifaceted nature of the MIC13 protein and its significance in immunological processes. Conclusion: These findings suggest that MIC13 could serve as a key component in the creation of a successful vaccine targeting T. gondii. The results obtained from this research lay a solid foundation for future investigations and offer valuable insights for the creation of successful vaccines to combat both acute and chronic toxoplasmosis through diverse strategies.